Erythropoietin modulates bone marrow stromal cell differentiation

Area of Science:

• Bone Biology and Endocrinology
• Hematopoiesis and Cellular Differentiation
• Mesenchymal Stem Cell Biology

Background:

• Erythropoietin (EPO) is crucial for red blood cell production.
• EPO receptors are present on non-erythroid cells, including bone marrow stromal cells (BMSCs), suggesting broader systemic roles.
• Abnormal EPO levels are linked to various physiological changes.

Purpose of the Study:

• To investigate the role of endogenous and exogenous erythropoietin signaling in bone marrow stromal cell differentiation.
• To determine the impact of chronic EPO overexpression and EPO treatment on bone and bone marrow cellularity.
• To elucidate the specific effects of erythropoietin receptor (EpoR) expression in erythroid versus non-erythroid cells on bone metabolism.

Main Methods:

• Utilized genetically modified mouse models: Tg6 (chronic EPO overexpression) and ΔEpoR_E (erythroid-restricted EpoR).
• Administered exogenous EPO treatment to wild-type and ΔEpoR_E mice.
• Assessed bone parameters (trabecular and cortical bone), bone marrow adipocyte content, and hematocrit.
• Transplanted BMSCs from different mouse models into immunodeficient mice to evaluate their differentiation potential in vivo.
• Analyzed bone morphogenic protein (BMP) signaling pathways.

Main Results:

• Chronic EPO overexpression (Tg6 mice) led to high hematocrit, reduced bone mass, fewer bone marrow adipocytes, and impaired BMP2-induced bone/adipocyte formation.
• Exogenous EPO treatment mimicked these effects, reducing bone and adipocytes without increasing osteoclasts, and suppressing BMP signaling.
• Endogenous EPO is essential for normal BMSC differentiation into osteoblasts and adipocytes.
• ΔEpoR_E mice showed reduced bone and increased adipocytes, with impaired BMP2-induced bone formation.
• EPO treatment in ΔEpoR_E mice normalized hematocrit without bone loss, indicating a non-erythropoietic role in bone reduction.
• Transplantation studies revealed that high EPO inhibits osteogenesis/adipogenesis, while loss of EpoR signaling favors adipogenesis over osteogenesis.

Conclusions:

• Endogenous EPO signaling is a key regulator of bone marrow stromal cell fate.
• Aberrant EPO levels, whether high or low signaling through non-erythroid EpoR, lead to impaired BMSC differentiation.
• These findings highlight a critical, non-hematopoietic role of EPO in maintaining bone homeostasis and suggest therapeutic implications for conditions with altered EPO levels.